Skip to content
Boca Raton City Online – Lifestyle
Author:
Actuate Therapeutics
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
November 2, 2026
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
October 27, 2026
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
September 9, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
June 9, 2026
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
June 1, 2026